

1 Appendix A Metastatic sites and anatomical
2 distribution




Fig. A1 Illustration created to inform networks conveying information about the complexity of the disease. All sites found in the cohort were set as nodes by using their approximate anatomical locations on a 2D plane.

		Responder at 4 weeks	Enrollment at 1 year	PFS \geq 9 months	BOR
Total number of sites	t0	0.3096	0.3199	0.2816	1
	t1	0.3519	0.1555	0.2316	0.7693
	t2	0.2	0.05094	0.05945	0.2423
Peritoneal sites	t0	0.3423	0.9376	0.7529	0.7006
	t1	0.2258	0.7857	0.6676	0.5249
	t2	0.2231	0.3286	0.2234	0.1356
Lymph nodes sites	t0	0.4432	0.8147	0.9374	0.3484
	t1	0.4432	0.8147	0.9374	0.3484
	t2	0.186	0.8127	0.4749	0.8631
Other sites	t0	0.851	0.2548	0.173	0.4074
	t1	0.851	0.2548	0.173	0.4074
	t2	0.851	0.2548	0.173	0.4074

Table A1 Kruskal-Wallis testing for the number of sites against the different response assessment measurements.




Fig. A2 Number of edges in the anatomical network for every patient and time point.




Fig. A3 Temporal evolution of distance dissemination measurements for the whole cohort.




Fig. A4 Comparison of total distance between sites for every response assessment measurement.




Fig. A5 Comparison of the maximum distance between two sites for every response assessment measurement.

	t0	t1	t2
RUQ	3 [1, 7]	3 [1, 6]	3 [1, 5]
LUQ	2 [1, 9]	3 [1, 15]	2 [1, 5]
Mesentery	5.5 [1, 11]	5 [2, 15]	4 [2, 9]
LPG	2.5 [1, 4]	2 [2, 4]	1.5 [1, 2]
RPG	2 [2, 3]	2 [1, 15]	2 [2, 6]
Pelvis	1 [1, 3]	1 [1, 3]	1 [1, 1]
Peritoneum other	2 [1, 3]	2 [1, 3]	3 [1, 3]
Lesser sac transverse mesocolon	1 [1, 3]	1 [1, 4]	2 [2, 2]
Infrarenal abdominal LN	3 [1, 13]	2 [1, 6]	2 [1, 8]
Suprarenal abdominal LN	3 [1, 6]	3 [1, 7]	3.5 [1, 6]
Supradiaphragmatic LN	2 [1, 14]	1 [1, 8]	1.5 [1, 8]
Ingual LN	1 [1, 3]	1 [1, 3]	1 [1, 4]
Chest LN	1 [1, 11]	2 [1, 14]	3 [1, 11]
Pleura	10.5 [7, 14]	11.5 [4, 19]	6.5 [4, 9]
Lung	11 [9, 23]	8 [7, 21]	11 [3, 30]

Table A2 Number of lesions per site and timepoint. The numbers correspond to the median and the range.




Fig. A6 Number of lesions for the whole patient cohort. Differences between timepoints are assessed through paired sample Wilcoxon signed-rank testing.




Fig. A7 Pearson correlation between the number of lesions and the number of sites.

3 Appendix B Volumetric Analyses




Fig. B1 Temporal evolution of the volume of every patient individual site in the cohort.




Fig. B2 Checkers of the volumetric relative site for the sites found in every patient and time point.




Fig. C1 Comparison of the overall of summed radiomic features for every response assessment.

4 Appendix C Radiomic Analyses




Fig. C2 Comparison of the range of the radiomic features for every response assessment.